Applied Therapeutics
APLT
About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Employees: 32
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $131K | Put options by funds: $76K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
18% less funds holding
Funds holding: 89 [Q1] → 73 (-16) [Q2]
28.99% less ownership
Funds ownership: 91.14% [Q1] → 62.15% (-28.99%) [Q2]
47% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 30
47% less capital invested
Capital invested by funds: $51.8M [Q1] → $27.3M (-$24.5M) [Q2]
50% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 28
Financial journalist opinion
